Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AMRI 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AMRI 3Q

Large-scale manufacturing revenue up 14%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI

3Q Revenues: $55.8 million (+11%)
 
3Q Loss: $2.1 million (loss of $5.9 million 3Q11)
 
YTD Revenues: $159.5 million (-1%)
 
YTD Loss: $5.7 million (loss of $7.9 million YTD11)
 
Comments: Total contract revenue for the quarter was $45.6 million, up 4%. Large Scale manufacturing revenue was $29.3 million (+14%). Discovery Services revenue was flat at $8.9 million. Development/Small-Scale Manufacturing revenue was $7.4 million (-20%). Royalty revenue in the quarter was $9.4 million (+45%) related to worldwide sales of Allegra, and certain generic forms of Allegra. Revenue in the quarter includes milestones totaling $0.8 million from the company’s 2005 licensing agreement with BMS.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters